OncoMatch

OncoMatch/Clinical Trials/NCT05838521

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Is NCT05838521 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab govitecan for cervical cancer.

Phase 2RecruitingYale UniversityNCT05838521Data as of May 2026

Treatment: Sacituzumab govitecan — This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Biomarker criteria

Required: TACSTD2 any tested (testing required; no eligibility threshold specified)

Disease stage

Required: Stage I, II, III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 2 prior lines
Min 1 prior line

Must have received: chemotherapy — recurrent or persistent cervical cancer

have progressed following at least one prior chemotherapy treatment regimen

Cannot have received: topoisomerase I inhibitor

Have previously received topoisomerase I inhibitors

Cannot have received: irinotecan (irinotecan)

Exception: history of anaphylactic reaction or ≥ Grade 3 toxicity

history of an anaphylactic reaction to irinotecan or ≥ Grade 3 toxicity to prior irinotecan

Lab requirements

Blood counts

WBC ≥ 3,000/ul, Platelets ≥ 75,000/ul, Granulocytes ≥ 1500/ul

Kidney function

creatinine ≤ 2.0 mg/dL

Liver function

bilirubin ≤ 1.5 institutional upper limit of normal, AST and ALT ≤ 2.5 × IULN or ≤ 5 × IULN if known liver metastases

adequate bone marrow function: WBC ≥ 3,000/ul, Platelets ≥ 75,000/ul, Granulocytes ≥ 1500/ul. adequate renal function: creatinine ≤ 2.0 mg/dL. adequate hepatic function: bilirubin ≤ 1.5 institutional upper limit of normal, AST and ALT ≤ 2.5 × IULN or ≤ 5 × IULN if known liver metastases

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
  • Cleveland Clinic · Cleveland, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify